Interventional Cardiology Devices Market

In 2025, drug-eluting stents are dominating the angioplasty stents market. The interventional cardiology devices market has seen increasing use of drug-eluting stents (DES), driven by high and rising rates of coronary artery disease and a strong clinical preference for DES because of their lower rates of restenosis and revascularization compared with bare-metal stents. Continuous technological innovations—thinner struts, improved polymer coatings, and next-generation antiproliferative drugs—have made the procedure safer and yielded superior long-term results, encouraging the use of these stents in complex and high-risk PCI cases. Furthermore, favorable reimbursement policies, strong clinical evidence from large U.S. trials, and well-established cath lab infrastructure contribute to the rapid growth of DES use in hospitals and outpatient cardiac facilities.

In 2025, the aortic heart valve device dominated the structural heart valve devices market. The expansion of aortic heart valve devices is the main driver of growth in the structural heart devices market. Rising cases of aortic stenosis, especially among the elderly, are driving the adoption of transcatheter aortic valve replacement (TAVR) as a standard minimally invasive procedure, thereby reducing the relative importance of open-heart surgery. Strong clinical trial results demonstrating improved survival rates, shorter hospital stays, and faster recovery have led to TAVR's acceptance among intermediate- and low-risk patient groups. In addition, ongoing innovation and improvements in devices, an increasing number of skilled doctors, favorable reimbursement policies in developed countries, and patients' growing preference for less invasive procedures are all helping to accelerate market growth.

In 2025, angiography catheters dominated the catheter market. The rising prevalence of cardiovascular diseases, a major driver of demand for diagnostic and interventional angiographic procedures, is a key factor behind the growth of the angiography catheters market. Innovations in catheter design, materials, and coating technologies have improved trackability, torque control, and patient safety, supporting broader clinical adoption. Additionally, the growing popularity of less invasive procedures, rising procedure volumes in hospitals and cath labs, and better access to modern imaging facilities are also contributing to higher demand for angiography catheters.

In 2025, the old/normal balloons dominated the angioplasty balloons market. The growth of traditional (plain old balloon) angioplasty balloons is mainly attributed to their economic viability, universal applicability in clinics, and continued use in lesion preparation and post-dilatation procedures across routine PCI cases. These balloons remain the most attractive option in developing regions and other areas where price is a major factor, as well as in complex cases that require vessel sizing, stent optimization, or pre-stent dilatation. Moreover, their ease of handling, compatibility with various guidewires and catheters, and a performance record that assures consistency create continued demand, even as drug-coated and specialty balloons become more available.

In 2025, Thrombectomy Devices dominated the plaque modification devices market. The rapid growth of thrombectomy devices in the plaque modification devices market has been driven mainly by the increasing occurrence of acute coronary syndromes and thrombus-rich lesions, which are common, especially in high-risk and complex PCI procedures. Rising acceptance of less invasive catheter-based treatments, along with increasing awareness among doctors of the advantages of thrombus removal in terms of better distal flow and fewer complications during the procedure, also supports demand. Moreover, the development of new technologies in aspiration and mechanical thrombectomy systems, the growing use of these systems in adjunctive PCI strategies, and the continued high volume of procedures in established cath lab infrastructures are some of the factors pushing the consumption of thrombectomy devices.

In 2025, Embolic Protection Devices dominated the Hemodynamic flow alteration devices market. The hemodynamic flow alteration devices market has been growing, driven by embolic protection devices (EPDs), as the number of complex interventional treatments, especially TAVR, carotid artery stenting, and high-risk PCI, increases, where the risk of distal embolization is high. Clinical efforts in stroke prevention and neuroprotection are intensifying, and wider adoption is being encouraged by growing procedural evidence and guideline awareness. Moreover, breakthroughs in filter and deflection technologies have expanded the use of EPDs into more structural heart interventions, so that, at times, even cardiac arrhythmia correction that is not part of the original procedure is performed with EPDs. The steady hospital focus on improving the safety and outcomes of procedures is also a fluctuating demand factor for embolic protection devices.

In 2025, guidewires dominated the other interventional cardiology devices market. The other interventional cardiology devices market has seen the guidewires sector grow due to the volume of percutaneous coronary interventions remaining high and constant, with guidewires being necessary in almost all procedures. Moreover, the treatment of complex and chronic total occlusion (CTO) lesions is on the rise, and greater acceptance of radial access methods are together increasing the demand for sophisticated guidewires with excellent torque control, flexibility, and support. Also, factors such as continuous product innovation, frequent replacement of single-use products, strong cath lab infrastructure, and wider application in coronary and structural heart interventions are among the major reasons that have led to the market's growth.

In 2025, hospitals dominated the interventional cardiology devices market by end user. They are the primary and major players in this market globally. Their growth is driven by high-volume, complex cardiac interventions, including PCI and structural heart procedures. This growth is further supported by rising cardiovascular disease prevalence, the adoption of advanced minimally invasive therapies such as TAVR and complex coronary interventions, and the presence of well-established cath lab infrastructure and skilled interventional cardiologists working in hospitals. Hospitals also benefit from good reimbursement for inpatient cardiac procedures, access to advanced imaging and hybrid operating rooms, and participation in clinical trials and physician training programs, which further accelerate market growth.